Navigation Links
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Date:6/25/2008

p>

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 may have important competitive advantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; no reproductive toxicity based on animal studies; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has completed a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second- generation MEK inhibitor for the treatmen
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Lockton Dunning Benefits, the Dallas ... addition of Vice President Kim Foerster ... Consulting team, Excelsior Solutions. Foerster ... the position.  Most recently, she worked as the ... Pharmacy, where she has held various managerial positions ...
(Date:12/24/2014)...  Medical Science Liaisons play a large role in ... medical device industry and key stakeholders, the role of ... as the device industry relies on them to build ... benchmarking firm, Best Practices, LLC, one area where Medical ... by harnessing new technology to enable education. Online conferences ...
(Date:12/22/2014)... --  TRU-D SmartUVC LLC, producers of the first ... that the General Services Administration has awarded the company ... This newly formed agreement will allow TRU-D SmartUVC ... including Department of Veteran Affairs and Department of Defense ... solutions for the Ebola effort in West ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... CoreLab Partners, Inc. has launched a new ... Medical Parameters for Solutions (A.M.P.S.) LLC. "We ... semi-automated CalECG v3 solution for the analysis of ECGs," ... Mike Woehler. "This new application represents our commitment to ...
... (ECIA:PK), a medical device company owning patented surgical technology that ... reported its financial results for its second fiscal quarter ended ... loss of $469,000 or $(0.07) per share for the second ... $2.830 million and net service revenue of $437 thousand. Total ...
Cached Medicine Technology:CoreLab Partners Now Offers Semi-automated ECG Solutions 2CoreLab Partners Now Offers Semi-automated ECG Solutions 3Encision Reports 14% Revenue Increase in Second Quarter Results 2Encision Reports 14% Revenue Increase in Second Quarter Results 3Encision Reports 14% Revenue Increase in Second Quarter Results 4
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... http://www.xareltolawsuit2015.com/ ) that allege the blood thinner caused ... has outlined a leadership structure for the proceeding, ... dated December 17th, the Court plans to select ... parties and also plans on appointing a Plaintiffs’ ...
(Date:12/24/2014)... 25, 2014 BambooIndustry.com a famous bamboo ... years. Today, the company announces its multiple layer ... offer on these new products. , Bamboo panel is ... The multiple layer bamboo panel board features high quality ... and emissions free. The bamboo panel consists of multiple ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Adults who ... risk of migraine headaches, suggests a study published ... . "Childhood maltreatment can have long-lasting effects, ... in adulthood," study author Dawn Buse, director of ... York City, said in a journal news release. ...
Breaking Medicine News(10 mins):Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... The Rajasthan government will come up with a bill seeking ... centres in the state, State Health Minister Digambar Singh said ... special bill in the next assembly session to monitor all ... check activities against the interests of the state and its ...
... revealed that a genetic deficiency of an important enzyme can ... //. The enzyme is one of a class of enzymes ... to stop cells from dividing. ,The study, ... National Institute of Child Health and Human Development. The NIH ...
... At the Medicines Policy Summit a new report looked at ... 2006 //. ,In the last six years, 78 new ... was the equivalent of Pharmac. Of these medicines, 72 are ... funded by Pharmac. ,The report showed that ...
... say that Medicare's new prescription drug programme is progressing ... day and cutting costs for each beneficiary by an average ... Texas, the scenario is quite different. ,A lot ... drugs they need. Pharmacists who are plagued with ...
... Medical College Hospital, Kerala they removed a five-and-a-half inch-long scissors ... Akkooppoyil Achuthan aged 65 was admitted in the hospital for ... he was discharged but frequented the hospital complaining acute pain ... scissors in the stomach. ,They team of doctors ...
... Union health minister Anbumani Ramadoss has asked movie stars, ... soft drink products by endorsing them, in the interest ... a congregation of health experts on Friday at the ... stated that the celebrities should stay away from endorsing ...
Cached Medicine News:Health News:Genetic Link to Adrenal Tumor Revealed 2Health News:A Baffling New Drug Plan In Texas Town 2Health News:Ramadoss Urges Celebrities Not To Endorse Soft Drinks 2
Cleveland Bone Cutter #5, 17cm, 6-3/4"...
Beuse Zygomatic Arch Awl with slightly curved tip....
Steroid-eluting, single-pass lead. CapSure VDD2 optimizes VDD therapy and offers easier handling, proven performance, and choice....
Steroid eluting pacemaker leads...
Medicine Products: